Literature DB >> 25460186

Inter-individual variation in the effect of antiepileptic drugs in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice.

Sabine Klein1, Marion Bankstahl1, Wolfgang Löscher2.   

Abstract

Despite more than 20 clinically approved antiepileptic drugs (AEDs), there remains a substantial unmet clinical need for patients with refractory (AED-resistant) epilepsy. Animal models of refractory epilepsy are needed for at least two goals; (1) better understanding of the mechanisms underlying resistance to AEDs, and (2) development of more efficacious AEDs for patients with refractory seizures. It is only incompletely understood why two patients with seemingly identical types of epilepsy and seizures may respond differently to the same AED. Prompted by this well-known clinical phenomenon, we previously evaluated whether epileptic rats respond differently to AEDs and discovered AED responsive and resistant animals in the same models. In the present study, we used the same approach for the widely used intrahippocampal kainate mouse model of mesial temporal lobe epilepsy. In a first step, we examined anti-seizure effects of 6 AEDs on spontaneous recurrent focal electrographic seizures and secondarily generalized convulsive seizures in epileptic mice, showing that the focal nonconvulsive seizures were resistant to carbamazepine and phenytoin, whereas valproate and levetiracetam exerted moderate and phenobarbital and diazepam marked anti-seizure effects. All AEDs seemed to suppress generalized convulsive seizures. Next we investigated the inter-individual variation in the anti-seizure effects of these AEDs and, in case of focal seizures, found responders and nonresponders to all AEDs except carbamazepine. Most nonresponders were resistant to more than one AED. Our data further validate the intrahippocampal kainate mouse model as a model of difficult-to-treat focal seizures that can be used to investigate the determinants of AED efficacy.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-seizure drugs; Hippocampus; Pharmacoresistance; Refractory seizures

Mesh:

Substances:

Year:  2014        PMID: 25460186     DOI: 10.1016/j.neuropharm.2014.11.008

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  20 in total

Review 1.  A Mesiotemporal Lobe Epilepsy Mouse Model.

Authors:  Duveau Venceslas; Roucard Corinne
Journal:  Neurochem Res       Date:  2017-03-23       Impact factor: 3.996

2.  Differential Effects of Antiepileptic Drugs on Focal Seizures in the Intrahippocampal Kainate Mouse Model of Mesial Temporal Lobe Epilepsy.

Authors:  Venceslas Duveau; Benoît Pouyatos; Karine Bressand; Céline Bouyssières; Tanguy Chabrol; Yann Roche; Antoine Depaulis; Corinne Roucard
Journal:  CNS Neurosci Ther       Date:  2016-02-22       Impact factor: 5.243

Review 3.  Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs.

Authors:  Wolfgang Löscher
Journal:  Neurochem Res       Date:  2017-03-13       Impact factor: 3.996

Review 4.  The Search for New Screening Models of Pharmacoresistant Epilepsy: Is Induction of Acute Seizures in Epileptic Rodents a Suitable Approach?

Authors:  Wolfgang Löscher
Journal:  Neurochem Res       Date:  2016-08-08       Impact factor: 3.996

5.  Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe Epilepsy.

Authors:  Alba Jimenez-Pacheco; Miguel Diaz-Hernandez; Marina Arribas-Blázquez; Amaya Sanz-Rodriguez; Luis A Olivos-Oré; Antonio R Artalejo; Mariana Alves; Michael Letavic; M Teresa Miras-Portugal; Ronan M Conroy; Norman Delanty; Michael A Farrell; Donncha F O'Brien; Anindya Bhattacharya; Tobias Engel; David C Henshall
Journal:  J Neurosci       Date:  2016-06-01       Impact factor: 6.167

6.  Antimuscarinic-induced convulsions in fasted animals after food intake: evaluation of the effects of levetiracetam, topiramate and different doses of atropine.

Authors:  Bahar Büget; Aslı Zengin Türkmen; Oruc Allahverdiyev; Nurhan Enginar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-10-09       Impact factor: 3.000

Review 7.  Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options.

Authors:  Wolfgang Löscher; Heidrun Potschka; Sanjay M Sisodiya; Annamaria Vezzani
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

8.  The matrix metalloproteinase inhibitor IPR-179 has antiseizure and antiepileptogenic effects.

Authors:  Diede Wm Broekaart; Alexandra Bertran; Shaobo Jia; Anatoly Korotkov; Oleg Senkov; Anika Bongaarts; James D Mills; Jasper J Anink; Jesús Seco; Johannes C Baayen; Sander Idema; Elodie Chabrol; Albert J Becker; Wytse J Wadman; Teresa Tarragó; Jan A Gorter; Eleonora Aronica; Roger Prades; Alexander Dityatev; Erwin A van Vliet
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

9.  In Vivo Studies of Drug BBB Transport: Translational Challenges and the Role of Brain Imaging.

Authors:  Stina Syvänen; Margareta Hammarlund-Udenaes; Irena Loryan
Journal:  Handb Exp Pharmacol       Date:  2022

10.  Recent update on barbiturate in relation to brain disorder.

Authors:  Sachchidanand Pathak; Gaurav Gupta; Lakshmi Thangavelu; Sachin K Singh; Kamal Dua; Dinesh Kumar Chellappan; Ritu M Gilhotra
Journal:  EXCLI J       Date:  2021-06-07       Impact factor: 4.068

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.